Compare iShares MSCI India ETF (INDA) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs Recursion Pharmaceuticals Inc — how do they compare? iShares MSCI India ETF trades at $46.03 (market cap $5.73B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: iShares MSCI India ETF is far larger — about 2.7× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI India ETF for 58 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| INDA | RXRX | |
|---|---|---|
Market Cap | $5.73B | $2.14B |
Volume | 6,797,522 | 30,789,535 |
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $6.79 |
52-Week Low | $45.42 | $2.84 |
Typical Hold Time | 58 Days | 23 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $46.03, down 0.2% on the day, with a bearish technical signal driven by moving averages and oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights India's economic growth amid sector-specific challenges, including energy security concerns and pharmaceutical export hurdles, which may influence the ETF's underlying holdings.
The outlook remains cautious due to technical weakness and macroeconomic headwinds in India. Opportunities exist if oversold conditions reverse, but risks include regulatory tensions and sector volatility. Investors should await updated financials for a clearer fundamental picture.
RXRX trades at $4.36, up 2.11% today, with technical indicators showing a bullish trend. The company reported Q3 2026 revenue of $54 million but continues to post significant losses with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche are expanding its AI-driven drug pipeline, though the stock faces high short interest and substantial cash burn from operations.
The outlook remains speculative given persistent losses and high valuation multiples (P/S 37.14), but analyst consensus leans positive with 40% buy ratings. Key risks include execution on drug development timelines and dependence on financing activities to fund operations. Upside potential hinges on successful clinical milestones from its expanding pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
